{"id":"cefuzonam","rwe":[{"pmid":"11896833","year":"2002","title":"The excretion of cephem antibiotics into saliva is inversely associated with their plasma protein-binding activities.","finding":"","journal":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","studyType":"Clinical Study"},{"pmid":"23989642","year":"1998","title":"Compatibility and stability of ranitidine hydrochloride with six cephalosporins during simulated y-site administration.","finding":"","journal":"International journal of pharmaceutical compounding","studyType":"Clinical Study"},{"pmid":"9593147","year":"1998","title":"Cloning and sequencing of the gene encoding Toho-2, a class A beta-lactamase preferentially inhibited by tazobactam.","finding":"","journal":"Antimicrobial agents and chemotherapy","studyType":"Clinical Study"},{"pmid":"8786627","year":"1996","title":"[In vitro activities of sulopenem, a new parenteral penem, against anaerobes].","finding":"","journal":"The Japanese journal of antibiotics","studyType":"Clinical Study"},{"pmid":"8786624","year":"1996","title":"[In vitro antibacterial activity of a new parenteral penem, sulopenem].","finding":"","journal":"The Japanese journal of antibiotics","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["cefuzonam","cefuzoname","cefuzonam sodium"],"offLabel":[],"synonyms":["cefuzonam","cefuzoname","cefuzonam sodium"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells are like houses, and the bacteria are like construction workers trying to build new houses. Cefuzonam stops the construction workers from making the walls of the new houses, effectively preventing the bacteria from growing and multiplying.","oneSentence":"Cefuzonam works by inhibiting bacterial cell wall synthesis.","technicalDetail":"Cefuzonam is a beta-lactam antibiotic that exerts its antibacterial effect by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, thereby inhibiting the synthesis of the bacterial cell wall and ultimately leading to cell lysis and death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3077","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFUZONAM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:31:16.924184","biosimilars":[],"competitors":[],"genericName":"cefuzonam","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"860MT00T7T","CHEBI":"CHEBI:55488","INN_ID":"5888","UMLSCUI":"C0055017","ChEMBL_ID":"CHEMBL1689069","KEGG_DRUG":"D01687","PUBCHEM_CID":"6336505","SECONDARY_CAS_RN":"82219-81-6","MESH_SUPPLEMENTAL_RECORD_UI":"C049934"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.14 hours","clearance":"4.1 mL/min/kg","fractionUnbound":"0.12%","volumeOfDistribution":"0.2 L/kg"},"publicationCount":112,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[{"date":"2002 Feb","pmid":"11896833","title":"The excretion of cephem antibiotics into saliva is inversely associated with their plasma protein-binding activities.","journal":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology"},{"date":"1998 Jul-Aug","pmid":"23989642","title":"Compatibility and stability of ranitidine hydrochloride with six cephalosporins during simulated y-site administration.","journal":"International journal of pharmaceutical compounding"},{"date":"1998 May","pmid":"9593147","title":"Cloning and sequencing of the gene encoding Toho-2, a class A beta-lactamase preferentially inhibited by tazobactam.","journal":"Antimicrobial agents and chemotherapy"},{"date":"1996 Apr","pmid":"8786627","title":"[In vitro activities of sulopenem, a new parenteral penem, against anaerobes].","journal":"The Japanese journal of antibiotics"},{"date":"1996 Apr","pmid":"8786624","title":"[In vitro antibacterial activity of a new parenteral penem, sulopenem].","journal":"The Japanese journal of antibiotics"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"CEFUZONAM","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefuzonam is a small molecule antibiotic developed by Hoechst Marion Roussel, currently owned by Sanofi. Its target and drug class are unknown. It has a half-life of 1.14 hours. Cefuzonam is not FDA approved for any indications. Its commercial status, generic manufacturers, and patent status are also unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}